News Archive

The National Academy of Inventors (NAI) has named Larry Gold, the founder and chairman of the board of SomaLogic, as one of its 2017 fellows. Election to NAI Fellow status is the highest professional distinction given to academic inventors. NAI Fellows are inventors on U.S. patents and were nominated by their peers for their spirit of innovation and creation of new technologies that have significantly impacted society.

An international team of researchers has defined the series of immune system changes that occur when tuberculosis (TB) transitions from a non-infectious state to active disease.

An article published online in Scientific Reports shows that Down syndrome may be a form of chronic immune disorder. In the largest and most comprehensive study of its kind to date, investigators at the Crnic Institute for Down Syndrome, the Sie Center for Down Syndrome, the University of Colorado, and Somalogic measured the levels of over 3500 proteins in the blood of Down syndrome patients and compared them to non-Down syndrome controls.

In an article published “early online” in the American Heart Association journal Circulation, researchers at Pfizer, the Karolinska Institute, the University of California, San Francisco and SomaLogic describe how the measurement of blood-based protein changes in response to treatment with an experimental drug candidate may improve the efficiency and safety of clinical drug development.

In a study published online in the Proceedings of the National Academy of Sciences (PNAS), SomaLogic scientists report on the generation and characterization of a new class of SOMAmer that contains two different types of modified nucleotides.

SomaLogic announced today that it has agreed to join the “Digital Life Alliance” established by iCarbonX, the China-based company founded in 2015 to build a “Global Digital Health Ecosystem that can define each person’s ‘digital life’ based on a combination of individual’s biological, behavioral and psychological data, the Internet and artificial intelligence.”

A study published online today in the Journal of the American Medical Association (JAMA) details the first successful effort to measure at scale the levels of more than a thousand proteins in blood in patients with coronary heart disease, and describes the identification of a combination of nine specific proteins whose levels taken together can accurately predict the risk of future heart attacks, strokes, heart failure or death.